Melovem (Meloxicam)

Meloxicam works by selectively blocking the cyclooxygenase‑2 (COX‑2) enzyme, which is responsible for producing prostaglandins that promote inflammation, pain, and fever. By reducing prostaglandin synthesis, meloxicam diminishes the inflammatory response, leading to decreased pain and swelling.

The appropriate dose of Melovem is determined by the prescribing clinician based on the patient’s condition, severity, age, renal and hepatic function, and other individual factors. Healthcare professionals tailor the regimen to achieve optimal therapeutic benefit while minimizing risk.

Safety of meloxicam in pregnancy or lactation has not been fully established. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Melovem. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Melovem (meloxicam) offers relatively selective COX‑2 inhibition, which may reduce gastrointestinal side effects compared with non‑selective NSAIDs like ibuprofen or diclofenac. However, it still carries cardiovascular and renal risks similar to other NSAIDs, and the choice of agent should be individualized based on patient risk profile.

Melovem should be stored at room temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Melovem is supplied as an oral tablet and is taken by mouth with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed by a healthcare professional.

The most serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, severe renal impairment, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for any signs of these complications.

Melovem should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal bleeding, severe heart failure, uncontrolled hypertension, or significant renal or hepatic impairment unless benefits outweigh risks. Pregnant women in the third trimester should also refrain from using it.